---
title: "Understanding the Market | LEADS BIOLABS-B rises over 6% again as Vailixin's Phase II study for frontline treatment of hepatocellular carcinoma enters the expansion stage"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295890883.md"
description: "LEADS BIOLABS-B rose over 6% again, with a cumulative increase of over 36% this month. As of the time of writing, it rose 6.07% to HKD 73.35, with a trading volume of HKD 131 million. In terms of news, LEADS BIOLABS recently announced that its self-developed PD-L1/4-1BB bispecific antibody, LBL-024, has completed the safety induction phase assessment of the Phase II clinical study for the first-line treatment of hepatocellular carcinoma, successfully entering the expansion phase. Public information shows that LBL-024 has demonstrated strong efficacy signals and breakthrough therapeutic potential in multiple tumor types, including lung neuroendocrine carcinoma, non-small cell lung cancer, small cell lung cancer, and cholangiocarcinoma. Based on the conditional activation design of the X-body® platform, its good safety has been validated in nearly 800 patients. This validation in liver cancer further solidifies LBL-024 as a safe cornerstone therapy for IO 2.0 pan-tumor treatment"
datetime: "2026-08-14T06:33:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295890883.md)
  - [en](https://longbridge.com/en/news/295890883.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295890883.md)
---

# Understanding the Market | LEADS BIOLABS-B rises over 6% again as Vailixin's Phase II study for frontline treatment of hepatocellular carcinoma enters the expansion stage

According to Zhitong Finance APP, LEADS BIOLABS-B (09887) has risen over 6% again, with a cumulative increase of over 36% this month. As of the time of publication, it is up 6.07%, priced at HKD 73.35, with a transaction volume of HKD 131 million.

In terms of news, LEADS BIOLABS recently announced that its self-developed PD-L1/4-1BB bispecific antibody, LBL-024, has completed the safety induction phase assessment of its Phase II clinical study for the first-line treatment of hepatocellular carcinoma, successfully entering the expansion phase after expert review.

Public information shows that LBL-024 has demonstrated strong efficacy signals and breakthrough therapeutic potential in multiple tumor types, including pulmonary neuroendocrine carcinoma, non-small cell lung cancer, small cell lung cancer, and cholangiocarcinoma. Based on the conditional activation design of the X-body® platform, its good safety has been validated in nearly 800 patients. This further validation in liver cancer solidifies LBL-024 as a safe cornerstone therapy for IO 2.0 pan-tumor treatment

### Related Stocks

- [09887.HK](https://longbridge.com/en/quote/09887.HK.md)

## Related News & Research

- [Nanjing Leads Biolabs Advances Key Liver Cancer Trial for Opamtistomig](https://longbridge.com/en/news/295043834.md)
- [Nanjing Leads Biolabs clarifies award grant to executive director is exempt connected transaction under HK rules](https://longbridge.com/en/news/294812838.md)
- [08:09 ETIterion Therapeutics Strengthens Board with Additions of Manuel Aivado, MD, PhD and Bob Smith](https://longbridge.com/en/news/295662552.md)
- [Can-Fite says Phase III namodenoson trial in advanced liver cancer advances under FDA, EMA guidance](https://longbridge.com/en/news/295654944.md)
- [Nanjing Leads Biolabs Wins Key ESMO Slots as Flagship Immunotherapy Assets Gain Momentum](https://longbridge.com/en/news/292463230.md)